|
|
 |
 |
| 6th Annual Biomarkers Congress is administered by Osney Media. |
|
|
|
|
 Speakers |
|
|
|
If you have a cutting edge case study or a presentation and would like to join the speaker panel at the 6th Annual Biomarkers Congress, please contact Mike Burden at m.burden@oxfordglobal.co.uk
Speakers already confirmed or reserved to speak at the 2011 Biomarkers Congress include:
|
· Donna L. Mendrick, Director, Division of Systems Biology, National Center for Toxicological Research, Food and Drug Administration
· Bruno Flamion, Chair, CHMP Scientific Advice Working Party, EMA
· Stefan Scherer, Global Biomarker Head, F. Hoffmann-La Roche / Genentech
· Nicholas Dracopoli, Vice President, Biomarkers, Centocor Research & Development, Johnson & Johnson
· Mark Jones, Associate Director Molecular Biomarkers, Global Exploratory Development, UCB New Medicines
· Stewart Bates, Director Biomarker Discovery, Biopharm R&D, GlaxoSmithKline
· Chris Chamberlain, Medical Director Personalised Medicine, AstraZeneca
· Dinesh De Alwis, Senior Research Advisor, Group Leader Global PK/PD – Europe, Eli Lilly
· Vicki Ikin, Clinical Biomarker Scientist Group Manager, AstraZeneca
· Arndt Schmitz, Founding Scientist, Research Biobank, Bayer Schering Pharma AG
· Gabriel Vargas, Biomarker Expert at Hoffmann-La Roche & Head of the CNS Clinical Biomarker Group
· Birgitte Søgaard, Divisional Director, Clinical Pharmacology and Translational Medicine, Lundbeck
· Maarten Van Roy, Associate Scientist, Pharmacology, Ablynx
· Niroshan Ramachandran, Senior Manager, Research and Development, Life Technologies |
· Patricia Hurley, Head of Project Management and Biomarkers Division, ERA Consulting (UK) Ltd
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stewart Bates, Director Biomarker Discovery, Biopharm R&D, GlaxoSmithKline
|
|
|
|
Chris Chamberlain, Medical Director Personalised Medicine, AstraZeneca
|
|
|
|
Dinesh De Alwis, Senior Research Advisor, Group Leader Global PK/PD, Europe, Eli Lilly
|
|
|
|
Nicholas Dracopoli, Vice President, Biomarkers, Centocor Research & Development, Johnson & Johnson
|
|
|
|
Bruno Flamion, Chair, CHMP Scientific Advice Working Party, EMA
|
|
|
|
Patricia Hurley, Head of Project Management and Biomarkers Division, ERA Consulting (UK) Ltd
|
|
|
|
Vicki Ikin, Clinical Biomarker Scientist Group Manager, AstraZeneca
|
|
|
|
Vicki Ikin, Clinical Biomarker Scientist Group Manager, AstraZeneca
|
|
|
|
Mark Jones, Director Experimental Medicine (Biomarkers), New Medicines, UCB New Medicines
|
|
|
|
Debra Klatte, Director, Integrative Biology, Boehringer Ingelheim
|
|
|
|
Donna L. Mendrick, Director, Division of Systems Biology, National Center for Toxicological Research, Food and Drug Administration
|
|
|
|
Niroshan Ramachandran, Senior Manager, Research and Development, Life Technologies
|
|
|
|
Stefan Scherer, Global Biomarker Head F. Hoffmann-La Roche / Genentech
|
|
|
|
Arndt Schmitz, Founding Scientist, Research Biobank, Bayer Schering Pharma AG
|
|
|
|
Peter Smith, Senior Scientist II, Oncology, Millennium Pharmaceuticals
|
|
|
|
Birgitte Søgaard, Divisional Director, Clinical Pharmacology and Translational Medicine, Lundbeck
|
|
|
|
Maarten Van Roy, Associate Scientist, Pharmacology, Ablynx
|
|
|
|
Gabriel Vargas, Biomarker Expert & Head of the CNS Clinical Biomarker Group F.Hoffmann-La Roche
|
|
|
|
|
|
|
|
|
|
|
